Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of anisodine hydrobromide injection in acute ischemic stroke after intravenous thrombolysis
CTR20222106Phase 3Active
- Sponsor
- Chengdu No. 1 Pharmaceutical
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anisodine in ischemic stroke, sponsored by Chengdu No. 1 Pharmaceutical. Started Nov 2022; status: active.
02
Drugs
anisodine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20222106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222106.